康至德榮獲《香港商業時報》的「年度最傑出分子醫學企業大獎」

我們很高興地宣布,Cognitact (康至德)在2024年3月14日榮獲由《Hong Kong Commercial Times 香港商業時報》頒發的「HKCT企業大獎2024 – 年度最傑出分子醫學企業」殊榮!

這個獎項是對我們過去一年在阿爾茲海默症血液生物標志物檢測領域的努力和成就的認可。評審團根據企業的成就、市場競爭力、品牌理念以及專業地位四個方面進行了全面評估。

未來,我們將繼續致力於阿爾茲海默症早期檢測和預防,為患者提供更優質的服務,提升市場競爭力。感謝大家一直以來的支持!讓我們一起攜手對抗阿爾茲海默症,創造更美好的未來!

 Exciting News! Cognitact was honored with the prestigious "HKCT Business Award 2024 – Most Outstanding Molecular Medicine Enterprise of the Year" by the Hong Kong Commercial Times on March 14, 2024!

This award is a testament to our relentless efforts and achievements in the field of Alzheimer's disease blood biomarker testing over the past year. The jury conducted a comprehensive assessment based on our accomplishments, market competitiveness, brand philosophy, and professional standing.

Looking ahead, we remain committed to the early detection and prevention of Alzheimer's disease, striving to provide cutting-edge technology to patients and enhance our market presence. Thank you for your unwavering support! Together, let's continue our fight against Alzheimer's and shape a brighter future!